Industry professionals, academics and FDA all agree that the cost of drug development is unsustainable, according a recent article on the San Francisco Business Times. To tackle the problem, FDA is looking at ways to change the drug development process. At the Personalized Medicine Conference, FDA’s Dr. Janet Woodcock described some of the ways FDA is accelerating the clinical trial process. Woodcock discussed everything from creating standing trial networks to the new “breakthrough therapies” initiative process. According to Woodcock, the initiative could cut the drug approval process to one stage with 30 to 50 patients. She also mentioned the need for more collaboration between industry, academia and patient groups. To read the full article, click here. Need help with a clinical trial? Contact us at 317-899-9341.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.